Tavneos trial flagged for 'serious breaches' of protocol as EU regulators dissect market withdrawal decision
EU regulators reversed Tavneos’ marketing authorization after the EMA’s CHMP cited “serious” good clinical practice breaches in the Advocate phase 3 trial, including unblinding and re-adjudication that changed week-52 results. CHMP also flagged serious hepatic safety risks. Tavneos was developed by ChemoCentryx, acquired by Amgen ($3.7B). CSL Vifor holds EU rights; Amgen contests the decision and seeks an FDA hearing.
How this was made
The 30-second read
Why it matters
This is a direct regulatory setback for Tavneos in the EU, with CHMP alleging unblinded access and post-unblinding re-adjudication that changed week-52 superiority results. The article also notes Amgen’s ongoing FDA defense via a third-party re-evaluation package and a requested hearing.
Market read
Traders should treat this as a heightened regulatory-risk catalyst for AMGN tied to Tavneos, with EU revocation and detailed CHMP rationale increasing uncertainty for the US process.
What to watch
US hearing timing, the strength of the third-party Advocate re-evaluation, and whether FDA focuses on specific GCP findings versus overall evidence could materially change the expected path.
Background
The EU Commission revoked Tavneos’ marketing authorization after CHMP flagged serious GCP breaches in the Advocate phase 3 trial and reported hepatic safety concerns, following earlier FDA withdrawal requests.
Ticker impact
Amgen is fighting to keep Tavneos on the market after the EU reversed marketing authorization, with CHMP citing serious GCP breaches and hepatic safety risks.
Near-term pressure on AMGN sentiment tied to Tavneos regulatory overhang; magnitude depends on US hearing trajectory and any additional FDA action.
The article details CHMP allegations of unblinding-driven endpoint reruns and fatal liver injury signals, and notes Amgen’s active defense with an FDA data package and hearing request.
Market effects
Raises scrutiny risk for complement inhibitor and rare-disease trial data integrity, potentially pressuring similar programs’ perceived regulatory survivability.
EU market access for Tavneos is removed, likely shifting patient demand and payer decisions away from the product in Europe.
EU regulator rationale mirrors FDA concerns, increasing probability of broader cross-regulator alignment on Tavneos and similar dossiers.
Counterpoint
Amgen argues real-world evidence and secondary endpoints support benefit-risk, so the EU decision may not fully translate into a US outcome.
Key entities
- drugTavneos
Complement inhibitor for ANCA-associated vasculitis whose EU marketing authorization was revoked amid trial-data integrity and hepatic safety concerns.
- companyAmgen
Acquired ChemoCentryx and is defending Tavneos’ US market position after EU revocation and FDA withdrawal back-and-forth.
- companyCSL Vifor
EU marketing operator for Tavneos that confirmed the European Commission’s final decision to revoke commercial clearance.
- regulatorCHMP (EMA)
EMA committee that published regulatory documents citing serious GCP breaches and fatal hepatic safety signals.
